William Blair analyst Matthew Phipps downgraded NuCana to Market Perform from Outperform after the company announced that the NuTide:323 study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee. The combination of NUC-3373 with leucovorin, irinotecan and bevacizumab was unlikely to achieve the study’s primary objective of superior progression free survival compared to the control arm, NuCana said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NCNA:
- NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments
- NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
- Biotech Alert: Searches spiking for these stocks today
- Investors should look at NuCana into fall data, says Oppenheimer
- Closing Bell Movers: H&R Block jumps 10% after earnings beat